RCUS - Arcus Biosciences Inc Stock Price, Fair Value and News

16.92USD-0.54 (-3.09%)Delayed

Market Summary

USD16.92-0.54

Delayed

-3.09%

RCUS Alerts

Big jump in Revenue (Y/Y)

Big jump in Earnings (Y/Y)
Losses in recent quarter

RCUS Stock Price

View Fullscreen

RCUS RSI Chart

RCUS Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

-6.66

Price/Sales (Trailing)

6.49

EV/EBITDA

-6.21

Price/Free Cashflow

-6.55

RCUS Price/Sales (Trailing)

RCUS Profitability

EBT Margin

-95.78%

Return on Equity

-32.67%

Return on Assets

-17.87%

Free Cashflow Yield

-15.27%

RCUS Fundamentals

RCUS Revenue

Revenue (TTM)

237.0M

Rev. Growth (Yr)

480%

Rev. Growth (Qtr)

367.74%

RCUS Earnings

Earnings (TTM)

-231.0M

Earnings Growth (Yr)

95%

Earnings Growth (Qtr)

95.06%

Breaking Down RCUS Revenue

Last 7 days

1.3%

Last 30 days

14.0%

Last 90 days

0.7%

Trailing 12 Months

-3.9%

How does RCUS drawdown profile look like?

RCUS Financial Health

Current Ratio

5.22

RCUS Investor Care

Shares Dilution (1Y)

24.41%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	237.0M	0	0	0
2023	119.0M	121.0M	120.0M	117.0M
2022	391.5M	409.1M	432.6M	112.0M
2021	85.7M	93.4M	38.4M	383.0M
2020	15.0M	15.0M	77.8M	78.0M
2019	8.9M	9.4M	6.8M	15.0M
2018	2.7M	3.9M	8.0M	8.4M
2017	0	0	0	1.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Arcus Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 27, 2024	jarrett jennifer	sold	-202,720	17.55	-11,551	chief operating officer
Mar 18, 2024	jarrett jennifer	sold	-240,941	17.9152	-13,449	chief operating officer
Feb 27, 2024	jaen juan c.	sold	-464,953	20.1	-23,132	president
Feb 27, 2024	jarrett jennifer	sold	-685,148	20.11	-34,070	chief operating officer
Feb 26, 2024	jarrett jennifer	sold	-492,819	20.07	-24,555	chief operating officer
Feb 26, 2024	jaen juan c.	sold	-78,234	20.06	-3,900	president
Jan 29, 2024	gilead sciences, inc.	bought	320,000,000	21.00	15,238,100	-
Jan 23, 2024	goeltz ii robert c.	acquired	-	-	22,000	chief financial officer
Jan 23, 2024	nuyten dimitry sa	acquired	-	-	28,000	chief medical officer
Jan 23, 2024	tang carolyn c.	acquired	-	-	26,700	general counsel

Which funds bought or sold RCUS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-5.45	-64,887	928,084	-%
May 16, 2024	COMERICA BANK	reduced	-10.95	-57,530	422,893	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-77.4	-4,917,180	1,414,280	-%
May 15, 2024	AMUNDI	added	42.5	16,829	141,959	-%
May 15, 2024	Laurion Capital Management LP	new	-	10,336,300	10,336,300	0.09%
May 15, 2024	Walleye Trading LLC	sold off	-100	-615,994	-	-%
May 15, 2024	DAFNA Capital Management LLC	reduced	-0.43	-70,078	4,374,820	1.00%
May 15, 2024	CITADEL ADVISORS LLC	added	28.63	1,430,760	6,700,910	-%
May 15, 2024	Squarepoint Ops LLC	sold off	-100	-622,068	-	-%
May 15, 2024	ORBIMED ADVISORS LLC	sold off	-100	-2,234,700	-	-%

Are Funds Buying or Selling RCUS?

Are funds buying RCUS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RCUS

No. of Funds

Unveiling Arcus Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	6.25%	4,680,716	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G
Jan 31, 2024	gilead sciences, inc.	35%	31,532,781	SC 13D/A
Jan 24, 2024	state street corp	5.66%	4,239,577	SC 13G
Jan 23, 2024	blackrock inc.	13.4%	10,035,170	SC 13G/A
Jul 06, 2023	gilead sciences, inc.	35%	25,586,953	SC 13D/A
Feb 14, 2023	pfm health sciences, lp	3.7%	6	SC 13G/A
Feb 14, 2023	biotechnology value fund l p	1.7%	1,236,002	SC 13G/A
Feb 10, 2023	ecor1 capital, llc	0%	0	SC 13G/A
Feb 09, 2023	vanguard group inc	6.04%	4,373,177	SC 13G

Recent SEC filings of Arcus Biosciences Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 24, 2024	ARS	ARS
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Mar 29, 2024	4	Insider Trading
Mar 27, 2024	144	Notice of Insider Sale Intent
Mar 20, 2024	4	Insider Trading
Mar 15, 2024	144	Notice of Insider Sale Intent
Feb 28, 2024	4	Insider Trading

Peers (Alternatives to Arcus Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Arcus Biosciences Inc News

Latest updates

Arcus Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	367.7%	145,000,000	31,000,000	32,000,000	29,000,000	25,000,000	34,000,000	33,000,000	27,000,000	18,000,000	354,617,000	9,461,000	9,461,000	9,461,000	9,970,000	64,530,000	1,750,000	1,750,000	9,750,000	1,750,000	1,750,000	1,750,000
Operating Expenses	32.0%	161,000,000	122,000,000	112,000,000	112,000,000	111,000,000	108,000,000	103,000,000	96,000,000	85,000,000	73,598,000	87,597,000	85,597,000	82,208,000	61,499,000	62,978,000	47,125,000	30,150,000	27,277,000	24,999,000	30,910,000	20,523,000
S&GA Expenses	-100.0%	-	29,000,000	30,000,000	28,000,000	30,000,000	28,000,000	26,000,000	26,000,000	24,000,000	23,010,000	16,343,000	16,826,000	15,821,000	13,383,000	11,177,000	11,432,000	7,008,000	6,590,500	7,758,000	5,911,000	4,969,000
R&D Expenses	17.2%	109,000,000	93,000,000	82,000,000	84,000,000	81,000,000	80,000,000	77,000,000	70,000,000	61,000,000	50,588,000	71,254,000	68,771,000	66,387,000	48,364,000	51,801,000	35,693,000	23,142,000	20,686,500	17,241,000	24,999,000	15,554,000
EBITDA Margin	63.3%	-0.92	-2.50	-2.35	-2.29	-2.27	-2.32	0.21	0.18	0.17	0.15	-3.12	-1.28	-	-	-	-	-	-	-	-	-
Income Taxes	-100.0%	-	1,000,000	2,000,000	1,000,000	2,000,000	-	-	-	1,000,000	2,000,000	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	95.0%	-4,000,000	-80,000,000	-69,000,000	-74,000,000	-78,000,000	-67,000,000	-65,000,000	-67,000,000	-67,000,000	281,538,000	-77,975,000	-75,970,000	-72,593,000	-	-	-	-	-	-	-	-
EBT Margin	62.8%	-0.96	-2.57	-2.40	-2.35	-2.33	-2.37	0.19	0.17	0.15	0.14	-3.21	-1.32	-	-	-	-	-	-	-	-	-
Net Income	95.1%	-4,000,000	-81,000,000	-71,000,000	-75,000,000	-80,000,000	-67,000,000	-65,000,000	-67,000,000	-68,000,000	279,538,000	-77,975,000	-75,970,000	-72,593,000	-51,853,000	1,822,000	-45,074,000	-27,753,000	-16,598,000	-22,352,000	-28,090,000	-17,670,000
Net Income Margin	62.9%	-0.97	-2.62	-2.44	-2.37	-2.34	-2.38	0.18	0.16	0.15	0.14	-7.26	-2.13	-	-	-	-	-	-	-	-	-
Free Cashflow	93.6%	-6,000,000	-94,000,000	-73,000,000	-62,000,000	-101,000,000	-70,000,000	-83,000,000	-66,000,000	651,000,000	-70,360,000	-61,615,000	-80,068,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	18.1%	1,293	1,095	1,191	1,220	1,254	1,345	1,394	1,477	1,543	1,592	839	899	935	772	811	481	176	203	217	239	259
Current Assets	28.0%	1,064	831	882	986	1,015	1,067	1,101	1,227	1,264	1,262	545	746	842	736	797	472	166	193	200	228	245
Cash Equivalents	45.7%	185	127	184	230	238	206	218	273	549	148	179	320	390	173	222	285	67.00	58.00	79.00	76.00	68.00
Net PPE	0%	51.00	51.00	50.00	45.00	37.00	35.00	34.00	33.00	33.00	32.00	29.00	24.00	15.00	11.00	9.00	8.00	9.00	9.00	10.00	10.00	11.00
Liabilities	-	-	-	-	-	-	-	695	729	747	750	297	294	270	270	267	53.00	36.00	39.00	40.00	42.00	37.00
Current Liabilities	10.9%	204	184	200	180	179	193	177	164	161	166	143	130	132	122	163	40.00	21.00	23.00	21.00	27.00	19.00
Shareholder's Equity	53.0%	707	462	520	566	600	657	699	747	797	842	543	605	665	502	544	429	141	164	177	197	222
Retained Earnings	-0.5%	-853	-849	-768	-697	-622	-542	-474	-409	-343	-275	-554	-476	-400	-328	-276	-278	-233	-205	-188	-166	-138
Additional Paid-In Capital	-	-	-	-	-	-	-	1,183	1,165	1,145	1,118	1,097	1,081	1,066	830	821	707	373	369	366	363	360
Shares Outstanding	20.4%	91.00	76.00	75.00	75.00	73.00	73.00	72.00	72.00	71.00	69.00	69.00	68.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,068	-	-	-	1,298	-	-	-	1,379	-	-	-	1,250	-	-	-	298	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	97.7%	-2,000	-88,000	-63,000	-57,000	-98,000	-70,000	-81,000	-65,000	654,000	-61,932	-53,757	-73,995	-66,316	-50,050	216,265	-23,938	-31,277	-9,471	-27,399	-19,753	-16,839
Share Based Compensation	11.1%	20,000	18,000	18,000	18,000	19,000	17,000	16,000	15,000	17,000	14,287	14,585	13,367	12,761	8,066	6,002	4,470	3,462	2,437	2,740	2,130	1,674
Cashflow From Investing	-703.6%	-169,000	28,000	11,000	26,000	129,000	47,000	23,000	-215,000	-268,000	18,782	-88,611	3,003	62,826	136	-387,119	-87,073	40,056	-12,104	30,364	26,673	14,279
Cashflow From Financing	7533.3%	229,000	3,000	6,000	23,000	1,000	11,000	3,000	4,000	15,000	11,331	1,318	2,231	222,120	2,002	107,518	328,870	610	520	-41.00	649	-5.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RCUS Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 145	$ 25
Operating expenses:
Research and development (Net of recoveries of $16 and $33 from a related party)	109	81
General and administrative	32	30
Impairment of long-lived assets	20	0
Total operating expenses	161	111
Loss from operations	(16)	(86)
Non-operating income (expense):
Interest and other income, net	13	9
Effective interest on liability for sale of future royalties	(1)	(1)
Total non-operating income, net	12	8
Loss before income taxes	(4)	(78)
Income tax expense	0	(2)
Net loss	$ (4)	$ (80)
Net loss per share, basic (in dollars per share)	$ (0.05)	$ (1.09)
Net loss per share, diluted (in dollars per share)	$ (0.05)	$ (1.09)
Shares used to compute loss per share, basic (in shares)	86.2	73.0
Shares used to compute loss per share, diluted (in shares)	86.2	73.0
License and Development Services Revenue
Revenues:
Total revenues	$ 135	$ 17
Other Collaboration Revenue
Revenues:
Total revenues	$ 10	$ 8

RCUS Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 185	$ 127
Marketable securities	810	632
Receivable from collaboration partners ($21 and $20 from a related party)	35	38
Prepaid expenses and other current assets	34	34
Total current assets	1,064	831
Long-term marketable securities	100	107
Property and equipment, net	51	51
Other noncurrent assets ($— and $6 from a related party)	78	106
Total assets	1,293	1,095
Current liabilities:
Accounts payable	16	17
Deferred revenue ($112 and $84 to a related party)	124	91
Other current liabilities	64	76
Total current liabilities	204	184
Deferred revenue, noncurrent ($209 and $291 to a related party)	242	307
Other noncurrent liabilities	140	142
Commitments
Stockholders’ equity:
Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 90.9 shares in 2024 and 75.5 shares in 2023 issued and outstanding	1,561	1,311
Accumulated deficit	(853)	(849)
Accumulated other comprehensive loss	(1)	0
Total stockholders’ equity	707	462
Total liabilities and stockholders’ equity	$ 1,293	$ 1,095

About Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

CEO	Dr. Terry J. Rosen Ph.D.
WEBSITE	arcusbio.com
INDUSTRY	Biotechnology
EMPLOYEES	500

Arcus Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Arcus Biosciences Inc? What does RCUS stand for in stocks?

RCUS is the stock ticker symbol of Arcus Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arcus Biosciences Inc (RCUS)?

As of Fri May 17 2024, market cap of Arcus Biosciences Inc is 1.54 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RCUS stock?

You can check RCUS's fair value in chart for subscribers.

What is the fair value of RCUS stock?

You can check RCUS's fair value in chart for subscribers. The fair value of Arcus Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arcus Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RCUS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arcus Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether RCUS is over valued or under valued. Whether Arcus Biosciences Inc is cheap or expensive depends on the assumptions which impact Arcus Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RCUS.

What is Arcus Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, RCUS's PE ratio (Price to Earnings) is -6.66 and Price to Sales (PS) ratio is 6.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RCUS PE ratio will change depending on the future growth rate expectations of investors.